Global Radiodermatitis Market Expected to Garner a Revenue of $561.7 Million by 2028, Growing at a CAGR of 4.1% from 2021-2028 – Exclusive Report [169 Pages] By Research Dive

The global radiodermatitis market is expected to experience an expeditious growth by 2028, owing to the surging cases of cancer worldwide. The tropical product sub-segment is expected to be most beneficial. The North America region is predicted to dominate in the global industry.


New York, USA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Research Dive has added a new report to its offering titled, “Radiodermatitis Market by Product (Topical, Oral, and Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028”.

According to the report, the global radiodermatitis market is anticipated to generate a revenue of $561.7 million, growing expeditiously at a CAGR of 4.1% during the forecast period (2021-2028).

Dynamics of the Market

Surging cases of cancer around the globe and the increasing adoption of radiotherapy among people are expected to drive the growth of the market during the forecast period. But lack of information exposure about acute or chronic radiodermatitis among people living in low income or underdeveloped countries is expected to impede the growth of the market during the forecast period. However, increasing awareness among people living in developed countries concerning the enhancement of their quality of life and enormous expansion of healthcare establishments across the globe are expected to create ample opportunities for the growth of the market during the forecast period.

Download PDF Sample Report of Radiodermatitis Market

COVID-19 Impact on the Market

The outbreak of coronavirus has had a negative impact on the growth of the global radiodermatitis market due to the prevalence of lockdowns across the globe. Lockdowns resulted in the closure of factories and industries, creating redundant disruption for both sellers and buyers. The supply and distribution channel of radiodermatitis products were adversely distorted, leading to the declined growth of the market during pandemic.

The Global Radiodermatitis Market to Experience a Boost Owing to the Increasing Number of Patients Suffering from Radiodermatitis

Segments of the Market

The report has divided the market into various segments based on product, distribution channel, and region.

  • By product, the tropical sub-segment is expected to be most beneficial and generate a revenue of $380.2 million during the forecast period. Surging demand for wound care options and availability of wide range of products like topical antibiotics, corticosteroids, hydrophilic creams, etc. are expected to bolster the growth of the sub-segment during the forecast period.

  • By distribution channel, the hospital pharmacy sub-segment is predicted to have the largest market share and generate a revenue of $243.6 million during the forecast period. Increasing geriatric population and elevated outpatient services provided by the sub-segment is expected to accelerate their growth during the forecast period.

  • By region, the North America radiodermatitis market is anticipated to have the largest market share and generate a revenue of $155.0 million during the forecast period. Increasing cases of cancer and availability of advanced innovative products in this region are expected to drive the growth of the regional market during the forecast period.

Get Access to Comprehensive Analysis of the Impact of Covid-19 on Radiodermatitis Market

Prominent Key Players of the Radiodermatitis Market

  1. AceTech
  2. 3M Company
  3. HARTMANN
  4. KeraNetics, Inc.
  5. Charles River Laboratories
  6. The Jackson Laboratory
  7. Stratpharma
  8. Smith & Nephew Plc.
  9. Molnlycke
  10. InterMed S.A.

These players are working on developing strategies such as product development, merger and acquisition, partnerships and collaborations to sustain the market growth. Inquire and Get Quick Access to Top Companies Development Strategies Summary Report

For instance, in June 2020, BioVentureHub, a Sweden-based medical technology company specializing in drugs, devices, digital health and diagnostics, collaborated with Molnlycke, a dominant medical technology company, in order to bolster innovation opportunities and drug-device therapies for a better future.

The report also summarizes many important aspects including financial performance of the key players, SWOT analysis, product portfolio, and latest strategic developments.

Top Trending Reports -

 

Contact Data